These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12056715)

  • 41. [Effectiveness and hematotoxicity of paclitaxel monotherapy in patients with advanced non-small cell bronchial carcinoma (NSCLC)].
    Leutz M; Schlimmer P; Zell L; Ukena D; Sybrecht G
    Pneumologie; 1997 Jan; 51(1):62-5. PubMed ID: 9132749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
    Uno Y; Hirano M; Murakami N; Kikuchi T; Nozawa H; Okuda T; Oya J; Kikkawa H
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):227-32. PubMed ID: 11865628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH; Paul DM; Hande KR; DeVore R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S; Sekine I; Saijo N
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
    Panday VR; ten Bokkel Huinink WW; Vermorken JB; Rosing H; Koopman FJ; Swart M; Schellens JH; Beijnen JH
    Pharmacol Res; 1999 Jul; 40(1):67-74. PubMed ID: 10378993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
    Teng XY; Guan ZZ; Yao ZW; Liu DG; Zhou NN; Luo HY; Hawkins M; Soon-Shiong P
    Ai Zheng; 2004 Nov; 23(11 Suppl):1431-6. PubMed ID: 15566651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.
    Smith RE; Brown AM; Mamounas EP; Anderson SJ; Lembersky BC; Atkins JH; Shibata HR; Baez L; DeFusco PA; Davila E; Tipping SJ; Bearden JD; Thirlwell MP
    J Clin Oncol; 1999 Nov; 17(11):3403-11. PubMed ID: 10550134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Re: Severe neurotoxicity in vinorelbine-paclitaxel combinations.
    Budman DR; Weiselberg L; O'Mara V
    J Natl Cancer Inst; 1997 Jan; 89(1):87-8. PubMed ID: 8978412
    [No Abstract]   [Full Text] [Related]  

  • 50. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
    Seidman AD; Hudis CA; Albanell J; Tong W; Tepler I; Currie V; Moynahan ME; Theodoulou M; Gollub M; Baselga J; Norton L
    J Clin Oncol; 1998 Oct; 16(10):3353-61. PubMed ID: 9779712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
    Sato K; Inoue K; Saito T; Kai T; Mihara H; Okubo K; Koh J; Mochizuki H; Tabei T;
    Jpn J Clin Oncol; 2003 Aug; 33(8):371-6. PubMed ID: 14523055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment.
    Ellerbroek N; Martino S; Mautner B; Tao ML; Rose C; Botnick L
    Breast J; 2003; 9(2):74-8. PubMed ID: 12603378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
    O'Connor TL; Kossoff E
    Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.
    Natale RB
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):34-7. PubMed ID: 8643968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
    Brenner B; Ilson DH; Minsky BD; Bains MS; Tong W; Gonen M; Kelsen DP
    J Clin Oncol; 2004 Jan; 22(1):45-52. PubMed ID: 14701767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
    Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.